# US 2025/0145732 A1 · Tissue factor pathway inhibitor antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145732 A1
- Document ID: US20250145732A1
- Status: Published application
- Kind: A1
- Application number: 18/937,384
- Filed: 2024-11-05
- Published: 2025-05-08
- Earliest claimed: 2015-08-19
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Debra Pittman; James R. Apgar; Zong Sean Juo; Macy Jin; Mark Stahl; Gregory J. Carven; Matthew Holsti; Susan Benard; Sunita R. Hett; Reema Jasuja
- Web page: https://patentgrep.com/patent/US20250145732A1

## CPC

- C07K 16/38: against protease inhibitors of peptide structure
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 39/0011: {Cancer antigens}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

An isolated antibody or antigen-binding fragment thereof that specifically binds to an epitope in Kunitz Domain 2 (K2) of Tissue Pathway Factor Inhibitor (TFPI), wherein the antibody comprises:
(a) a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR-H1) comprising the amino acid sequence of SEQ ID NO:48, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:49, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:50, and a light chain variable region (VL) comprising a VL complementarity determining region one (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 43, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:44, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:45;
(b) a VH comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 51, SEQ ID NO:67, SEQ ID NO:69, and SEQ ID NO:79 and a VL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:71, SEQ ID NO: 73, SEQ ID NO:75 and SEQ ID NO:77;
(c) a VH comprising the amino acid sequence of SEQ ID NO:51 and a VL comprising the amino acid sequence of SEQ ID NO:46;
(d) a heavy chain consisting of the amino acid sequence of SEQ ID NO:52 and a light chain consisting of the amino acid sequence of SEQ ID NO:47;
(e) a VH comprising the amino acid sequence of SEQ ID NO:67 and a VL comprising the amino acid sequence of SEQ ID NO:77; or
(f) a heavy chain consisting of the amino acid sequence of SEQ ID NO:68 and a light chain consisting of the amino acid sequence of SEQ ID NO:78.

### Claim 34 (depends on 33)

The antibody, or antigen-binding fragment thereof, of claim 33, wherein said antibody, or antigen-binding fragment thereof, binds to TFPI with a binding affinity (KD) value of from about 1×10−8 M to about 1×10−10 M.

### Claim 35 (depends on 33)

The antibody or antigen-binding fragment thereof of claim 33, wherein said antibody or antigen-binding fragment thereof:
(i) decreases clotting time as measured in a plasma based dilute prothrombin time assay;
(ii) reduces clotting time in whole blood as measured by thromboelastrography;
(iii) increases thrombin generation;
(iv) increases FXa activity in the presence of TFPI;
(v) enhances platelet accumulation in the presence of TFPI;
(vi) increases fibrin generation in the presence of TFPI; or
(vii) any combination thereof.

### Claim 36 (depends on 35)

The antibody or antigen-binding fragment thereof of claim 35, wherein said plasma or whole blood is deficient in Factor VIII or Factor IX.

### Claim 37 (depends on 33)

A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of claim 33, and a pharmaceutically acceptable carrier or excipient.

### Claim 38 (depends on 33)

The antibody, or antigen-binding fragment thereof, of claim 33, wherein said epitope comprises residues Glu100, Glu101, Asp102, Gly104, Ile105, Cys106, Arg107, Gly108, Tyr109, Cys130, Leu131 and Gly132, according to the numbering of SEQ ID NO:2.

### Claim 39

An isolated antibody or antigen-binding fragment thereof that specifically binds the K2 of TFPI, wherein said antibody or antigen-binding fragment comprises the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO:67, and the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO:77.

### Claim 40

An isolated antibody or antigen-binding fragment thereof that specifically binds the K2 of TFPI, wherein said antibody or antigen-binding fragment consists of a heavy chain comprising the amino acid sequence of SEQ ID NO:68 and a light chain comprising the amino acid sequence of SEQ ID NO:78.
